Read short, plain-language summaries of significant research papers that CCR scientists and their collaborators have contributed to the oncology research community.
Vol. 5, No. 2, 2011 - IL-15 Prepares for Its Clinical Debut. It’s been nearly two decades since CCR researcher Thomas Waldmann, M.D., co-discovered interleukin-15 (IL-15), a cytokine and potent stimulator of antitumor memory CD8+ T cells.
View the media coverage that results from seminal discoveries made by CCR's translational research teams.
Cancer has eluded us for centuries, but the researchers at NCI's Center for Cancer Research (CCR) remain undaunted. They are bringing real hope, real progress. Our camera will bring you into their labs and clinics to see this progress for yourself.
Resources for the Media and Public
Resources for Our Staff
Th17 Immune Cells in vivo: Friend or Foe? Upon encountering an antigen, T cells bearing CD4+ (a helper marker) proliferate and become polarized. Learn more...
Mapping Cancer Cells’ Starting Lines Many of the defective regulatory pathways that lead to aberrant proliferation in cancer converge on DNA replication. Learn more...
Targeted Infrared Photoimmunotherapy for Cancer A longstanding goal of cancer therapy is the extensive destruction of cancer cells with minimal collateral damage to normal cells. Learn more...
IL-15 Prepares for Its Clinical Debut Thomas Waldmann, M.D., and his colleagues have started testing interleukin-15 (IL-15), a promising new candidate in cancer immunotherapy, in human patients for the first time.
Imaging Minimally Invasive Surgery Peter Choyke, M.D., and Peter Pinto, M.D., have combined their skills in advanced imaging techniques and laser therapy to potentially revolutionize prostate cancer treatment.
Man’s Best Friend in More Ways Than One Chand Khanna, D.V.M., Ph.D., is working to improve the assessment of novel treatments for humans by treating pet animals—primarily dogs with naturally occurring cancers—while also trying to give these animals a better quality of life by offering them the benefit of cutting-edge research and experimental therapies.
A service of the National Cancer Institute
